Core Insights - The latest research reveals that sensory nerves within tumors are a key factor causing immune therapy resistance in some triple-negative breast cancer patients, which is known for its high malignancy and low survival rates [1][2]. Group 1: Research Findings - The study, led by a team from Fudan University, identifies that sensory nerves in triple-negative breast cancer tumors create a barrier that prevents immune cells from effectively penetrating the tumor [2]. - A significant correlation was found between the presence of peripheral nerve invasion in pathology samples and poor patient prognosis, indicating that this is an important signal for predicting ineffective immune therapy [2]. - The research indicates that when sensory nerves are active, they form a dense matrix barrier within the tumor, which blocks immune cell access, leading to suboptimal treatment outcomes for patients [2]. Group 2: Treatment Implications - The study suggests that a drug commonly used for migraine treatment can enhance the effectiveness of immune therapy by inhibiting sensory nerves, thereby weakening the barrier and allowing immune cells to enter the tumor [2][4]. - This innovative approach represents a shift towards utilizing existing clinical drugs in new ways to improve cancer treatment outcomes, potentially shortening the clinical translation cycle [4]. - The findings emphasize the need for a holistic view of cancer treatment that integrates the roles of nerves, tumors, and immune responses, paving the way for more precise therapies for breast cancer [4].

Core Viewpoint - The article discusses the evolution of the "Hallmarks of Cancer" theory, expanding from six to nine characteristics and introducing four dimensions to better understand cancer complexity [2][3]. Group 1: Evolution of Cancer Characteristics - In 2000, Douglas Hanahan and Robert Weinberg first proposed six hallmarks of cancer: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis [5]. - In 2011, two additional hallmarks were added: deregulating cellular energetics and escaping immune destruction. By 2022, the ninth hallmark, "unlocking phenotypic plasticity," was introduced [6]. Group 2: Nine Hallmarks of Cancer - The newly added ninth hallmark refers to cancer cells' ability to change their identity and characteristics, explaining the diversity of cell types within tumors and their adaptability to treatment pressures [9]. Group 3: Four Dimensions of Cancer Complexity - The new framework categorizes cancer complexity into four dimensions: 1. The nine hallmarks themselves, which are core capabilities for cancer cell survival and development [11]. 2. Five enabling characteristics, including genomic instability, tumor-promoting inflammation, neural regulation, polymorphic microbiome, and non-mutational epigenetic reprogramming, which facilitate the acquisition of the nine hallmarks [12]. 3. Various cells in the tumor microenvironment, such as cancer cells, senescent cells, cancer-associated fibroblasts, neurons, endothelial cells, and immune cells, which assist cancer cells in acquiring necessary features [12]. 4. Systemic interactions, highlighting cancer as a systemic disease interacting with other parts of the body [13]. Group 4: Focus on Neural Regulation - "Cancer neuroscience" has emerged as a significant area of focus, revealing that nerves not only surround tumors but also communicate closely with cancer cells. In some cases, cancer cells form "synapse-like" connections with nerves, receiving growth signals through neurotransmitters [20][21]. Group 5: Microbiome's Role in Cancer - The microbiome, consisting of bacteria, fungi, and viruses, has a profound impact on cancer. The composition of an individual's microbiome can influence cancer development and treatment responses [22][23]. - The gut microbiome may affect the efficacy of cancer immunotherapy by modulating the immune system. Studies indicate that fecal transplants from responding patients can enhance treatment effects in non-responders [24][25]. Group 6: Future Directions in Cancer Treatment - Scientists propose a "feature-coordinated targeting" treatment strategy, aiming to target multiple cancer characteristics simultaneously to prevent the emergence of resistance mechanisms [26]. - Successful clinical examples include combinations of anti-angiogenic drugs with immune checkpoint inhibitors showing superior effects in certain cancers. Future treatments may involve combinations targeting different cancer features, guided by advancements in single-cell sequencing and spatial transcriptomics [30][31].

Core Viewpoint - The 22nd National Conference on Otorhinolaryngology-Head and Neck Surgery (CSOHNS2025) showcased the significant contributions and academic influence of Yantai Yuhuangding Hospital's Otorhinolaryngology-Head and Neck Surgery department, highlighting their clinical and research capabilities in the field [1][5][6]. Group 1: Conference Participation and Achievements - The conference gathered top experts and scholars in the field, with Yantai Yuhuangding Hospital's team actively participating through 11 presentations, 1 fourth-place finish in a national endoscopic competition, and over 10 research results shared in poster sessions [1][5]. - Professor Song Xicheng presented a report on "Neuroscience of Head and Neck Squamous Cell Carcinoma," which attracted significant attention and discussion among attendees, emphasizing the hospital's academic influence in head and neck tumor research [2][5]. - The hospital's team members held various leadership roles during the conference, including chairing specialized sessions, which facilitated high-quality academic exchanges [2][3]. Group 2: Recognition and Academic Positions - Professor Song Xicheng was appointed as a member of the Chinese Medical Association's Otorhinolaryngology Physician Assessment Committee and elected as the Vice Chairman of the Committee for Postgraduate Medical Education in Otorhinolaryngology, further establishing the hospital's academic standing [2][3]. - The hospital's team demonstrated a strong presence across various sub-forums, with multiple presentations on cutting-edge research topics, showcasing their expertise and contributions to the field [4][5]. Group 3: Quality Control and Future Directions - The National Otorhinolaryngology Quality Control Center held a meeting to summarize annual quality control work, aiming to enhance the understanding of core medical quality safety systems and promote standardized practices in the field [3]. - The conference served as a platform for the hospital to strengthen its commitment to improving medical service quality and academic innovation, contributing to the development of the Otorhinolaryngology-Head and Neck Surgery discipline in China [6].

Core Viewpoint - The study published in Nature highlights the role of cancer-induced nerve injury (CINI) in promoting resistance to anti-PD-1 therapy, emphasizing the importance of exploring cancer neuroscience for potential therapeutic targets [4][5][10]. Group 1: Cancer-Induced Nerve Injury (CINI) and Its Mechanism - CINI occurs when cancer cells damage the protective myelin sheath of peripheral nerves, leading to chronic inflammation and immune exhaustion, which ultimately results in resistance to immunotherapy [4][10]. - The study reveals that targeting CINI-related signaling pathways can reverse chronic inflammation and improve the efficacy of cancer immunotherapy [4][12]. Group 2: Tumor-Associated Nerves (TAN) and Immune Response - Tumor-associated nerves (TAN) are recognized as poor prognostic factors in various cancers, including skin squamous cell carcinoma, melanoma, gastric cancer, and pancreatic ductal adenocarcinoma [7][11]. - The interaction between cancer cells, TAN, and tumor immune activity is crucial, as damaged TAN can recruit immune cells that promote tumor progression and contribute to anti-PD-1 therapy resistance [8][11]. Group 3: Clinical Implications and Future Directions - The findings suggest that CINI and its associated chronic inflammation mediate the mechanisms of resistance to anti-PD-1 therapy, providing a basis for identifying biomarkers and developing therapeutic drugs to overcome resistance in cancer patients [12]. - Multi-faceted interventions targeting CINI pathways, such as denervation of tumors and blocking specific inflammatory signals, have shown potential in reversing anti-PD-1 resistance [11][12].

Core Viewpoint - The study reveals the complex interactions between neurons and glioblastoma cells, highlighting long-range cholinergic input as a significant factor in glioblastoma progression, providing new insights for cancer neuroscience research [4][8]. Group 1: Research Findings - The research team created a comprehensive brain connectivity map of glioblastoma (GBM) cells, demonstrating the influence of long-range cholinergic neurons on GBM progression [4][9]. - Local inputs are primarily glutamatergic, while long-distance connections exhibit diverse neurotransmitter characteristics, with cholinergic projections from the basal forebrain being a conserved input across different regions [7][9]. - The study identifies that acetylcholine release through muscarinic receptor CHRM3 promotes GBM growth in a circuit-specific manner, and blocking both acetylcholine and glutamate pathways results in an additive anti-tumor effect [10] [9]. Group 2: Implications for Treatment - Anticholinergic drug scopolamine inhibits GBM growth, while acetylcholinesterase inhibitor donepezil exacerbates the condition, indicating the potential for targeted therapies based on neurotransmitter signaling [4][7]. - The findings suggest that long-range neural regulatory pathways could serve as promising therapeutic targets for glioblastoma treatment [8].